UroGen Pharma Ltd. (URGN)
NASDAQ: URGN
· Real-Time Price · USD
7.38
2.24 (43.58%)
At close: Jun 06, 2025, 3:59 PM
7.55
2.37%
After-hours: Jun 06, 2025, 05:59 PM EDT
43.58% (1D)
| Bid | 7.5 |
| Market Cap | 340.04M |
| Revenue (ttm) | 91.87M |
| Net Income (ttm) | -138.43M |
| EPS (ttm) | -3.01 |
| PE Ratio (ttm) | -2.45 |
| Forward PE | -4.01 |
| Analyst | Buy |
| Ask | 7.76 |
| Volume | 19,665,261 |
| Avg. Volume (20D) | 1,285,071 |
| Open | 5.33 |
| Previous Close | 5.14 |
| Day's Range | 5.24 - 8.21 |
| 52-Week Range | 3.42 - 20.70 |
| Beta | 0.40 |
About URGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol URGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for URGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 days ago
+14.15%
UroGen Pharma sahres are trading higher after the ...
Unlock content with
Pro Subscription
2 weeks ago
-44.69%
UroGen shares are trading lower after the Oncologic Drugs Advisory Committee of the FDA voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution.
